Cameron Turtle

CEO Cameron Turtle sells 15,000 SYRE shares for $1.1M via scheduled 10b5-1 plan on 2026-06-01

Cameron Turtle, Chief Executive Officer of Spyre Therapeutics, executed three separate sales totaling 15,000 shares for $1,056,486.02 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-06-20. This transaction is scheduled, not discretionary. The company generated $0.00 in revenue in its latest quarter and reported a net loss of $-69,005,000.00, with negative full-year net income. Turtle's prior trades at SYRE show mixed price action: the five prior sells from 2026-05-01 posted 90-day returns ranging from -6.8% to -0.6%, while his cross-ticker track record across 12 prior sells averaged a 90-day return of +22.9%. The stock currently trades at $73.52, which is -6.7% from its 52-week high of $78.80 and +6.4% over the past 30 days.

CEO Turtle Cameron sells over $1M in SYRE stock across six tranches on same day

Turtle Cameron, Spyre's Chief Executive Officer, executed a coordinated liquidation of over $1M in company stock across six separate trades in a single trading session, reducing his holdings by roughly three percent. The transactions span a narrow price range and occur against a backdrop of fundamental deterioration — the company is burning cash at a significant rate with no revenue generation, making this CEO sell particularly notable as a potential signal that leadership sees limited near-term catalysts to drive upside. The methodical, high-volume nature of the sale (multiple tranches rather than one lump transaction) suggests a deliberate exit strategy rather than a routine rebalancing. For a pre-revenue biotech burning substantial quarterly losses, a sitting CEO liquidating this scale of personal holdings during a single session warrants scrutiny into whether management retains confidence in the company's value proposition or capital runway.

CEO Turtle Cameron sells 15,000 shares (2.3% of holdings) at $49.20–$49.92 amid revenue decline and $11.2M net loss

Turtle Cameron, CEO of unprofitable Spyre Therapeutics, executed 2 separate sales totaling 15,000 shares for $739,912.32 on 2026-04-01, at prices ($49.20 and $49.92) near the 52-week high of $50.44. This represents a -2.3% reduction in his 642.5K-share pre-transaction position. The stock has since declined to $47.58 (current price), widening the margin between sale prices and today's market. Spyre reported $0.00 in latest quarterly revenue and a net loss of $11.2M, indicating a cash-burn biotech in pre-revenue stage. His prior trades at SYRE show positive 30d and 90d returns (averaging +26.9% at 30 days and up to +39.2% at 90 days), yet the 90-day well-timed rate at this ticker stands at 0 of 2 prior measurable outcomes—suggesting he has not historically sold before declines at this company. The execution near the 52-week high and the company's fundamental unprofitability warrant investor attention to cash runway and cash-burn trajectory.

CEO Turtle Cameron sells 15,000 shares (15.0K) for $632.9K at $42.19 avg; stock now $40.07, down 9.3% from high

Turtle Cameron, CEO of Spyre Therapeutics, executed 2 separate sales totaling 15,000 shares for $632,866.00 on 2026-03-02, reducing his holdings from 657,540 to 642,540 shares (-2.3%). The sales occurred at an average price of $42.19, while the stock currently trades at $40.07, representing a gap of $2.12 per share. Notably, his prior 2 sales at SYRE (both on 2025-11-03) were followed by positive 30-day and 90-day returns, indicating the stock subsequently rose after those transactions; his same-ticker timing pattern shows 0 of 2 prior sells were well-timed at the 90-day mark. The company reported $0.00 revenue in its latest quarter and a net loss of $11,183,000.00, with negative profitability across its most recent full fiscal year, providing material context for insider disposition during a period of operational challenges.

CEO Turtle Cameron sells 45,000 shares (45.0K) for $1.0M at blended average $23.33 while company burns through net losses of $-11.2M with zero revenue.

CEO Turtle Cameron executed two separate sales totaling 45,000 shares for $1,049,777.85 on 2025-11-03, reducing his holdings from 746.9K to 701.9K shares (-6.0%). The transactions occurred at a blended average price of $23.33, which sits above the current price of $22.85 but notably -42.3% below the 52-week high of $39.58. Spyre Therapeutics reported zero revenue in its latest quarter and a full-year net loss of $-11.2M, indicating the company remains in a preclinical or very early-stage development phase burning cash. The timing and magnitude of this sale by the company's top executive merit scrutiny given the combination of severe operational losses, the absence of revenue generation, and the stock's recent volatility (up 37.1% in 30 days and 49.9% in 90 days from depressed levels).